Pasar al contenido principal

Josep A Villena Delgado

I earned my PhD in Biological Sciences at the University of Barcelona and I am currently a principal investigator of the Research Unit in Diabetes and Metabolism, where I lead the Laboratory of Metabolism and Obesity. The research carried out by my team focuses on understanding the mechanisms that regulate energy balance and glucose homeostasis, and how alterations in such mechanisms contribute to the pathogenesis of metabolic disorders, such as obesity, insulin resistance or diabetes. I am also coordinator and professor of the endocrine diseases section of the VHIR’s Master in Translational Biomedical Research.

Instituciones de las que forman parte

Investigador/a principal
Diabetes y Metabolismo
Vall Hebron Institut de Recerca

Josep A Villena Delgado

Instituciones de las que forman parte

Investigador/a principal
Diabetes y Metabolismo
Vall Hebron Institut de Recerca

I earned my PhD in Biological Sciences at the University of Barcelona and I am currently a principal investigator of the Research Unit in Diabetes and Metabolism, where I lead the Laboratory of Metabolism and Obesity. The research carried out by my team focuses on understanding the mechanisms that regulate energy balance and glucose homeostasis, and how alterations in such mechanisms contribute to the pathogenesis of metabolic disorders, such as obesity, insulin resistance or diabetes. I am also coordinator and professor of the endocrine diseases section of the VHIR’s Master in Translational Biomedical Research.

I obtained a degree in Biological Sciences by the University of Barcelona, where I also earned my PhD in Biology. The work of my PhD thesis focused on the identification of the transcription factors involved in the regulation of mitochondrial biogenesis. From 1999 to 2000, I worked as a postdoctoral researcher at the Rangueil University Hospital/CNRS (Toulouse, France) to investigate the role of adipose precursor cells on the immune function. In 2000, I moved to the University of California (Berkeley, USA). There, my work was dedicated to unveil the mechanisms involved in the differentiation and function of adipose cells and their impact on body weight and glucose homeostasis. The results of my work contributed to elucidate the function of Pref-1 as an inhibitor of adipogenesis and the identification of a new triglyceride lipase (Desnutrin/ATGL). In 2004. I joined The Scripps Research Institute (La Jolla, USA) as a research associate, where I worked on the role of Estrogen-Related Receptors in the control of mitochondrial biogenesis and the thermogenic function of brown adipose tissue. In 2007, after being awarded a “Ramon y Cajal” researcher position, I joined VHIR as a principal investigator. Since then, I lead the Laboratory of Metabolism and Obesity, integrated within the Unit of Diabetes and Metabolism. The most recent research of my team has allowed to precisely define the role of PGC-1s co-activators on adipose tissue mitochondrial biogenesis in response to anti-diabetic drugs or nutritional interventions, such a caloric restriction. Moreover, our work on cardiac metabolism in the context of diabetes led to the identification of ERRgamma as a factor potentially involved in the pathogenesis of diabetic cardiomyopathy. Our current research lines focus on the identification of the factors driving the resolution of obesity-associated meta-inflammation, which is considered to be at the origin of most of the comorbidities associated with this metabolic disease.

As a principal investigator, I have led numerous research projects funded by public (MINECO, MICINN) and private (La Marató de TV3, Fundació La Caixa) funding bodies. Among others, I currently coordinate OBESIMM, an international multicentric study aimed at defining the effects that intermittent feeding has on inflammation and the immune function of obese individuals. I am also a member of ADIPOBROAD, a national network of research groups for the study of adipose tissue plasticity and its impact on human health, as well as a member of the Spanish Society of Biochemistry and Molecular Biology, where I coordinate the study group on Metabolic Regulation and Nutrition.

Proyectos

OBESIMM - Explorando los efectos de la alimentación restringida en el tiempo sobre la funcióin inmune de individuos obesos: una aproximación multi-ómica

IP: Josep A Villena Delgado
Colaboradores: Rosario Pardo Diaz, Andreea Ciudin Mihai, Marta Comas Martínez, Ramón Vilallonga Puy, Enzamaría Fidilio Meli
Entidad financiadora: Instituto de Salud Carlos III
Financiación: 248050
Referencia: AC22/00023
Duración: 01/01/2023 - 31/12/2025

Control of the adipose-pancreatic crosstalk by mitochondrial metabolism in adipose tissues: implications in the development of diet-induced type 2 diabetes

IP: Josep A Villena Delgado
Colaboradores: Rosario Pardo Diaz, Berta Pares Bofill, Irene Hernández Hernández
Entidad financiadora: Ministerio Economía, Industria y Competitividad
Financiación: 145200
Referencia: RTI2018-099250-B-I00
Duración: 01/01/2019 - 30/09/2022

Dissecting the functional role of the epicardium metabolism during heart development and repair after myocardial infarction

IP: Josep A Villena Delgado
Colaboradores: -
Entidad financiadora: Fundació "La Caixa"
Financiación: 163900
Referencia: FBLC/HR17-00627/VILLENA
Duración: 01/01/2019 - 31/03/2023

Paper del receptor nuclear RORgamma com a mediador dels efectes de la restricció calòrica en teixit adipós

IP: Josep A Villena Delgado
Colaboradores: Miriam Izquierdo Sans
Entidad financiadora: Fundació Institut de Recerca HUVH
Financiación: 47268
Referencia: 2018/VHIR/VILA
Duración: 15/03/2019 - 14/03/2022

Noticias relacionadas

El proyecto europeo, en el que participa Vall d’Hebron, favorecerá el diagnóstico personalizado y estrategias terapéuticas innovadoras en pacientes con la enfermedad.

La Unidad de Tratamiento Integral de la Obesidad Pediátrica ha recibido la acreditación de centro de excelencia de la Asociación Europea para el Estudio de la Obesidad, consolidando un modelo que ofrece tratamiento en todas las etapas de la vida

Esta inversión de EIT Health en el proyecto permitirá a D-Sight avanzar en el desarrollo clínico de su innovador tratamiento para las primeras fases de la retinopatía diabética.

Profesionales relacionados

Jorge Pamias Romero

Jorge Pamias Romero

Nuevas Tecnologías y Microcirugía Craniofacial
Leer más
Luis Enrique Lara Moctezuma

Luis Enrique Lara Moctezuma

Fisiopatología Renal
Leer más
Jorge Leno Colorado

Jorge Leno Colorado

Técnico de investigación
Medicina Genética
Leer más
José Manuel Vidal Taboada

José Manuel Vidal Taboada

Investigador/a principal
Sistema Nervioso Periférico
Leer más

Suscríbete a nuestros boletines y forma parte de la vida del Campus

Vall d'Hebron Barcelona Hospital Campus es un parque de referencia mundial donde la asistencia, la investigación, la docencia y la innovación se dan la mano.